Sublingual Immunotherapy

Sublingual immunotherapy induced clinically significant desensitization with a favorable safety profile among children with peanut allergy, according to a study published in The Journal of Allergy and Clinical Immunology.

Allergy immunotherapy is effective in achieving long-term results for allergic rhinitis in real-world treatment, according to a study published in The Journal of Allergy Clinical Immunology.

Adolescents aged 12 to 17 years with allergic rhinitis induced by house dust mites now can take a sublingual immunotherapy tablet approved by the FDA after review of multiple trials in this age group.

The FDA approved house dust mite allergen extract tablet for sublingual immunotherapy treatment of house dust mite-induced allergic rhinitis in patients aged 12 to 17 years, according to a press release from the manufacturer.

Sublingual immunotherapy does more than relieve symptoms of respiratory allergy in children. It also modifies the disease, according to a review published in Allergy and Asthma Proceedings as part of its Allergen Immunotherapy (AIT) Primer.

Researchers have associated a variant of the HLA-DPB1 gene with poor responsiveness to sublingual immunotherapy for Japanese cedar pollinosis, according to a study published in Allergy.

House dust mite sublingual immunotherapy tablets reduced inhaled corticosteroid use among patients with mild to moderate allergic asthma, according to a systematic review in The Journal of Allergy and Clinical Immunology: In Practice.

A study found that “significant desensitization” occurred among peanut-allergic toddlers following peanut sublingual immunotherapy, according to data presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology.

Researchers demonstrated that long-term use of sublingual immunotherapy, or SLIT, was an effective and safe option to treat peanut allergy in children aged 1 to 11 years, according to findings published in The Journal of Allergy and Clinical Immunology.